Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trials

10 clinical trials for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) — RECRUITING · PHASE1
• A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. — RECRUITING · PHASE1
• CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia — NOT_YET_RECRUITING
• A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) — ACTIVE_NOT_RECRUITING · PHASE1
• BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL — ACTIVE_NOT_RECRUITING · PHASE1
• CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) — TERMINATED · PHASE1
• Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies — OTHER · PHASE1
• Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia — WITHDRAWN · PHASE1

Refine this search